Cargando…
De-risking clinical trial failure through mechanistic simulation
Drug development typically comprises a combination of pre-clinical experimentation, clinical trials, and statistical data-driven analyses. Therapeutic failure in late-stage clinical development costs the pharmaceutical industry billions of USD per year. Clinical trial simulation represents a key der...
Autores principales: | Brown, Liam V, Wagg, Jonathan, Darley, Rachel, van Hateren, Andy, Elliott, Tim, Gaffney, Eamonn A, Coles, Mark C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514113/ https://www.ncbi.nlm.nih.gov/pubmed/36176591 http://dx.doi.org/10.1093/immadv/ltac017 |
Ejemplares similares
-
Combining Mathematical Models With Experimentation to Drive Novel Mechanistic Insights Into Macrophage Function
por: Jansen, Joanneke E., et al.
Publicado: (2019) -
Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patients
por: Kmieciak, Aleksandra E., et al.
Publicado: (2021) -
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable
por: Brown, Liam V., et al.
Publicado: (2022) -
Recent advances in Major Histocompatibility Complex (MHC) class I antigen presentation: Plastic MHC molecules and TAPBPR-mediated quality control
por: van Hateren, Andy, et al.
Publicado: (2017) -
Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire
por: Illing, Patricia T., et al.
Publicado: (2021)